Log in

NASDAQ:TIG - TIGENIX/S Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume17,200 shs
Average Volume1,268 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases. The company's lead product candidate is the Cx601, which completed Phase III clinical trials for the treatment of complex perianal fistulas in patients suffering from Crohn's disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TIG
CUSIPN/A
Phone321-639-6060

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive TIG News and Ratings via Email

Sign-up to receive the latest news and ratings for TIG and its competitors with MarketBeat's FREE daily newsletter.


TIGENIX/S (NASDAQ:TIG) Frequently Asked Questions

What is TIGENIX/S's stock symbol?

TIGENIX/S trades on the NASDAQ under the ticker symbol "TIG."

Has TIGENIX/S been receiving favorable news coverage?

News headlines about TIG stock have trended extremely negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. TIGENIX/S earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for TIGENIX/S.

Who are some of TIGENIX/S's key competitors?

What other stocks do shareholders of TIGENIX/S own?

Who are TIGENIX/S's key executives?

TIGENIX/S's management team includes the folowing people:
  • Dr. Claudia D'Augusta, Chief Financial Officer and Compliance Officer (Age 48)
  • Mr. Wilfried Dalemans, Chief Technical Officer (Age 60)
  • Claudia Jiménez, Sr. Director of Investor Relations & Communications
  • An Moonen, Gen. Counsel and Company Sec.
  • Dr. Marie Paule Richard, Chief Medical Officer (Age 63)

When did TIGENIX/S IPO?

(TIG) raised $26 million in an initial public offering on Thursday, December 15th 2016. The company issued 2,800,000 shares at a price of $9.12 per share. BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is TIGENIX/S's official website?

The official website for TIGENIX/S is http://www.tigenix.com/.

How can I contact TIGENIX/S?

TIGENIX/S's mailing address is ROMEINSE STRAAT 12 BOX 2 3001, LEUVEN C9, 3001. The company can be reached via phone at 321-639-6060 or via email at [email protected]


MarketBeat Community Rating for TIGENIX/S (NASDAQ TIG)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  256 (Vote Outperform)
Underperform Votes:  362 (Vote Underperform)
Total Votes:  618
MarketBeat's community ratings are surveys of what our community members think about TIGENIX/S and other stocks. Vote "Outperform" if you believe TIG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TIG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Featured Article: Profit Margin

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel